Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

TB treatment mystery: why do some patients suddenly worsen?

NCT ID NCT04052022

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This study aims to understand why some people with tuberculosis (TB) experience a paradoxical reaction, where they initially improve on treatment but then suddenly get worse. Researchers will follow 140 adults with TB, with or without signs of this reaction, using blood tests, urine samples, and PET/CT scans over 6 to 18 months. The goal is to identify immune and imaging patterns that could help predict and manage these reactions in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict and manage paradoxical reactions in TB patients, improving treatment outcomes.
What could go wrong
This is an observational study, not a treatment trial. It may not lead to immediate clinical changes, and results depend on a small, specific group of participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2019

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be recruited from clinics in the surrounding Washington, DC area for the NIH site; and from clinics in Mexico for the foreign site

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: Suspected Paradoxical Reaction Group Criteria: 1. Aged greater than or equal to 18 years. 2. Diagnosed with confirmed (microbiologically or with molecular methods) or suspected (clinical plus or minus histologic diagnosis) TB and currently on ATT for a minimum of 2 weeks, or have completed ATT, with at least 2 of the following signs/symptoms of a paradoxical inflammatory reaction: * Recrudescent symptoms of TB after initial clinical improvement. * Change in physical exam after initial clinical improvement suggestive of new inflammatory process (e.g., lymphadenopathy or new findings on pulmonary exam). * Worsening radiographic evidence of disease after initiation of treatment, as compared with imaging prior to or earlier in treatment. * Laboratory evidence of acute inflammatory response, including the development of leukocytosis (white blood cell count \> 10,000 cells/microL) or a change of C-reactive protein (CRP) \> 5 mg/L compared to prior laboratory values. * Worsened organ function after initial clinical improvement. 3. The above sign/symptom(s) cannot be explained by a newly acquired infection, clinical course of a previously recognized infectious agent, side effects of the ATT, the presence of drug resistance, or any other condition except for paradoxical reaction. 4. Willingness to allow storage of blood or tissue samples for future research. 5. Ability of participant to understand study requirements and give informed consent. 6. Has a primary care physician and is being followed by the local Department of Health for their TB (or has plans to arrange after enrollment if enrolled early in course from inpatient transfer). Control Group Criteria: 1. Aged greater than or equal to 18 years. 2. Diagnosed with confirmed (microbiologically or with molecular methods) or suspected (clinical plus or minus histologic diagnosis) TB. 3. Presenting 2 to 4 months after starting ATT to match timing of paradoxical reactions. 4. Willingness to allow storage of blood or tissue samples for future research. 5. Ability of participant to understand study requirements and give informed consent. 6. Has a primary care physician and is being followed by the Department of Health for their TB (or has plans to arrange after enrollment if enrolled early in course from inpatient transfer). EXCLUSION CRITERIA: Individuals in either group who meet any of the following criteria will be excluded from study participation: 1. HIV infection. (Individuals with HIV infection may be eligible for a separate study exclusively evaluating persons living with HIV.) 2. Pregnant or breastfeeding. 3. Uncontrolled psychiatric disease, substance use, or inappropriate conduct unsuitable for a research study. 4. Malignancy requiring imminent or ongoing treatment including radiation, chemotherapy, or immunotherapy. 5. Debilitating or chronic conditions that would limit ability to participate in the study. 6. Emergent or urgent clinical conditions not due to studied disease of interest requiring immediate treatment that would be unsuitable for a research study. These patients would be transferred to an emergency room and able to rescreen when condition has been stabilized.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tuberculosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mexican Emerging Infectious Diseases Clinical Research Network (LaRed)

    RECRUITING

    Alcaldia Tlalpan, 14050, Mexico

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.